Johnson & Johnson gains 4% after publishing Q2 results

Johnson & Johnson (JNJ.US) shares are gaining 4% during today's session, after the drug and healthcare products manufacturer reported second-quarter results that exceeded analysts' expectations. On the other hand, the company lowered its adjusted earnings per share forecast for the full year due to costs associated with mergers and acquisitions resulting from recent transactions. However, it seems that in the eyes of investors, higher costs incurred now will be offset by higher profits in the future.

ANNUAL FORECAST

• Expected adjusted earnings per share (EPS) $9.97 to $10.07, previously $10.57 to $10.72
• Expected adjusted operating EPS $10 to $10.10, previously $10.60 to $10.75
• Expected revenues between $88 billion to $88.4 billion (unchanged)

SECOND QUARTER RESULTS

• Adjusted EPS $2.82, estimated $2.71
• Revenues $22.45 billion, estimated $22.32 billion
• MedTech revenues $7.96 billion, estimated $8.22 billion
• Pharmaceutical division revenues $14.49 billion, estimated $14.08 billion

Source: xStation